1. Topical treatment of tyrosine kinase 2 inhibitor through borneol-embedded hydrogel: Evaluation for preventive, therapeutic, and Recurrent management of psoriasis
- Author
-
Yuhsien Lai, Xuesong Wu, Zhuoyu Jiang, Yifei Fang, Xiuting Liu, Dan Hong, Yanyun Jiang, Guozhen Tan, Shiqi Tang, Siyao Lu, David Wei, Sam T. Hwang, Kit S. Lam, Liangchun Wang, Yanyu Huang, and Zhenrui Shi
- Subjects
Psoriasis ,Topical hydrogel ,Transdermal delivery ,Tyrosine kinase 2 inhibitor ,Borneol ,Materials of engineering and construction. Mechanics of materials ,TA401-492 ,Biology (General) ,QH301-705.5 - Abstract
Psoriasis, an immune-mediated inflammatory skin disorder characterized by a chronically relapsing-remitting course, continues to be primarily managed through topical therapy. While oral administration of tyrosine kinase 2 inhibitors (TYK2i) stands as an effective approach for psoriasis treatment, the potential efficacy of topical application of TYK2i remains unexplored. Herein, the carbomer/alginic acid hydrogel is embedded with borneol (BO) as a new topical carrier of TYK2i for achieving enhanced transdermal permeation and anti-psoriasis efficacy. The hydrogel system, i.e., TYK2i-BO-gel, exhibits significantly improved preventative and therapeutic effects in mice models of psoriasiform dermatitis, as evidenced by phenotypical images, psoriasis severity score index (PSI), histology, immunohistochemical staining, and PCR analysis. Remarkably, TYK2i-BO-gel outperforms conventional topical corticosteroid therapy by significantly preventing psoriatic lesion recurrence as measured by a nearly 50 % reduction in ear thickness changes (p
- Published
- 2024
- Full Text
- View/download PDF